Advice for Community Physicians Treating Patients with Neuroendocrine Tumor-Associated Carcinoid Syndrome
Drs Das, Pommier, and Zacks share their advice for community physicians treating patients who have neuroendocrine tumors with carcinoid syndrome and carcinoid heart disease.
Unmet Needs for Patients with Neuroendocrine Tumor-Associated Carcinoid Syndrome
Experts comment on the current unmet needs for patients with neuroendocrine tumor-associated carcinoid syndrome.
Prevention, Treatment, and Management of Carcinoid Heart Disease
Dr Jerome Zacks explains strategies to prevent, treat, and manage carcinoid heart disease, and emphasizes the need for multidisciplinary approaches.
Data from the TELEPATH Trial and Real-World Analyses
Dr Pommier discusses key safety, efficacy, and quality of life data from the TELEPATH trial investigating the tryptophan hydroxylase inhibitor telotristat ethyl, while Dr Das comments on real-world data complements to the trial.
Available Treatment Options for Somatostatin Analog-Refractory Carcinoid Syndrome
A medical oncologist reviews the currently available, NCCN-approved treatments for somatostatin analog-refractory carcinoid syndrome.
Diagnosis and Management of Somatostatin Analog-Refractory Carcinoid Syndrome
Dr Rodney Pommier gives an overview of somatostatin analog-refractory carcinoid syndrome and the recommended approaches for management in patients.
Management of Carcinoid Syndrome-Related Symptoms
Dr Satya (Nanu) Das discusses the typical management strategies for carcinoid syndrome-related symptoms, highlighting the use of somatostatin analogs.
Overview of Carcinoid Heart Disease (CHD)
Jerome Zacks, MD, explains carcinoid heart disease and its symptoms, and why it develops in some patients with NET-associated carcinoid syndrome.
Overview of Carcinoid Syndrome (CS)
Rodney Pommier, MD, defines carcinoid syndrome and describes the process of diagnosis and clinical risk factors in patients.
Overview of Neuroendocrine Tumors (NETs)
Satya (Nanu) Das, MD, MSCI, provides an overview of the incidence rate and common symptoms of neuroendocrine tumors (NETs).
Later-Line Ruxolitinib Use Produces Ongoing Benefit in Real-World Patients With cGVHD
Orca-T Data With Survival, Tolerability Extends to Older Patients With Hematologic Cancers
Dr Ramdial on Gemcitabine/Clofarabine/Busulfan for Lymphoma Stem Cell Transplant
Retrospective Analysis Shows Post-HCT Survival Benefits With Orca-T Vs PTCy in Hematologic Malignancies
2 Commerce Drive Cranbury, NJ 08512